Fluconazole-resistant Candida: Collateral damage associated with prior antibacterial exposure?

Future Microbiology

Volumn 7, Issue 9, 2012, Pages 1029-1031

  Ben Ami, Ronen ^a,b   Giladi, Michael ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

antibacterial agents; azoles; candidemia; drug resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBAPENEM; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; ECHINOCANDIN; FLUCONAZOLE; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; PYRROLE DERIVATIVE; SULFONAMIDE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; BACTERIAL INFECTION; BLOODSTREAM INFECTION; CANDIDA; CANDIDA ALABRATA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; DEATH; GENE EXPRESSION REGULATION; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK FACTOR; SEPTIC SHOCK; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CANDIDA; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; ISRAEL;

CANDIDA;

EID: 84866123956     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.83     Document Type: Review

References (30)

1. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48(12), 1695-1703 (2009).
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin. Infect. Dis. 41(9), 1232-1239 (2005).
3. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit. Care Med. 34(3), 857-863 (2006).
4. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3(11), 685-702 (2003).
5. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin. Infect. Dis. 54(12), 1739-1746 (2012).
6. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin. Infect. Dis. 43(1), 25-31 (2006).
7. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49(9), 3640-3645 (2005).
8. Grim SA, Berger K, Teng C et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: Correlation with outcomes. J. Antimicrob. Chemother. 67(3), 707-714 (2012).
9. Ben-Ami R, Weinberger M, Orni-Wasserlauff R et al. Time to blood culture positivity as a marker for catheter-related candidemia. J. Clin. Microbiol. 46(7), 2222-2226 (2008).
10. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: CANDIDA glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112(11), 2493-2499 (2008).
11. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): Stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115(20), 4745-4752 (2009).
12. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48(5), 503-535 (2009).
13. Ben-Ami R, Olshtain-Pops K, Krieger M et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob. Agents Chemother. 56(5), 2518-2523 (2012).
14. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6(11), e280 (2008).
15. Lee I, Morales KH, Zaoutis TE, Fishman NO, Nachamkin I, Lautenbach E. Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections. Am. J. Infect. Control 38(9), 740-745 (2010).
16. Lin MY, Carmeli Y, Zumsteg J et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: A case-case-control study. Antimicrob. Agents Chemother. 49(11), 4555-4560 (2005).
17. Lee I, Fishman NO, Zaoutis TE et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch. Intern. Med. 169(4), 379-383 (2009).
18. Structure, function and diversity of the healthy human microbiome. Nature 486(7402), 207-214 (2012).
19. Manichanh C, Reeder J, Gibert P et al. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res. 20(10), 1411-1419 (2010).
20. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108(Suppl. 1), 4554-4561 (2011).
21. Pultz NJ, Stiefel U, Ghannoum M, Helfand MS, Donskey CJ. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob. Agents Chemother. 49(1), 438-440 (2005).
22. Chang MR, Cury AE. Amphotericin B-metronidazole combination against Candida spp. Rev. Iberoam. Micol. 15(2), 78-80 (1998).
23. Cury AE, Hirschfeld MP. Interactions between amphotericin B and nitroimidazoles against Candida albicans. Mycoses 40(5-6), 187-192 (1997).
24. Beggs WH. Combined activity of ketoconazole and sulphamethoxazole against Candida albicans. J. Antimicrob. Chemother. 10(6), 539-541 (1982).
25. Zhai B, Zhou H, Yang L et al. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother. 65(5), 931-938 (2010).
26. De Micheli M, Bille J, Schueller C, Sanglard D. A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol. Microbiol. 43(5), 1197-1214 (2002).
27. Henry KW, Cruz MC, Katiyar SK, Edlind TD. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob. Agents Chemother. 43(8), 1968-1974 (1999).
28. Ben-Ami R, Olshtain-Pops K, Krieger M et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida spp. bloodstream infection. Antimicrob. Agents Chemother. doi:10.1128/AAC.05947-11 (2012) (Epub ahead of print).
29. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: Current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch. Intern. Med. 163(8), 972-978 (2003).
30. Srinivasan A, Fishman N. Antimicrobial stewardship 2012: Science driving practice. Infect. Control Hosp. Epidemiol. 33(4), 319-321 (2012).